






INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 501/56, A61K 31/545		A1	(11) International Publication Number: WO 99/65920
			(43) International Publication Date: 23 December 1999 (23.12.99)
(21) International Application Number: PCT/EP99/03907 (22) International Filing Date: 7 June 1999 (07.06.99) (30) Priority Data: 98110888.9 15 June 1998 (15.06.98) EP 98117099.6 10 September 1998 (10.09.98) EP (71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH]; Gren- zacherstrasse 124, CH-4070 Basle (CH). (72) Inventors: HEBEISEN, Paul; St. Alban-Ring 184, CH-4052 Basle (CH). HUBSCHWERLEN, Christian; Rue de la Gendarmerie, F-68200 Durmenach (FR). SPECKLIN, Jean-Luc; 2, rue des Faisans, F-68680 Kembs-Schaferhof (FR). (74) Agent: KJELLSAA-BERGER, Hanny; Grenzacherstrasse 124, CH-4070 Basle (CH).			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>

(54) Title: DERIVATIVES OF 3-(2-OXO-[1,3']BIPYRROLIDINYL-3-YLIDENEMETHYL)-CEPHEMS



(57) Abstract

The present invention is concerned with new compounds of formula (I) wherein R¹ is hydrogen, C₁₋₆-alkyl, optionally substituted by fluoro, or C₃₋₆-cycloalkyl; R² is hydrogen or a group selected from -CH₂C(=CHR)-COOR, -CH₂OCOR, -CH(R)OCOR, -CH(R)OCOOR, -CH(OCOR)OCOR, -CH₂COCH₂OCOR and (II); R³ is hydrogen or group selected from -CH₂C(=CH₂)-COOR, -COOCH₂C(=CHR)-COOR, -COOCH₂OCOR, -COOCH(R)OCOR, -CO CH(R)OCOOR, -COOCH(OCOR)OCOR, -COOCH₂COCH₂OCOR, and (III); with the proviso that one of R² and R³ is hydrogen and the other of R² and R³ is different from hydrogen, R is hydrogen or C₁₋₆-alkyl; R⁴ is hydrogen or hydroxy, R⁵ is hydrogen or ω-hydroxyalkyl; and X is CH or N, as well as pharmaceutically acceptable salts of said compounds and hydrates of said compounds and of their salts, and with the use of compounds of formula (I) and of pharmaceutically acceptable salts of said compounds and hydrates of said compounds and of their salts for the manufacture of pharmaceutical preparations containing such compounds.